Paris-based Edmond de Rothschild Investment Partners closed its newest venture capital fund for European life science companies at €192m (approximately US$250m).
Backers include Edmond de Rothschild Group and La Banque Publique d’Investissement (BPI France), as well as insurance companies, retirement funds, public pension funds, social institutions and other institutional investors.
BioDiscovery 4 will lead investments in 15 to 20 life sciences companies across all stages of development. The investments will be made in therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies.
It will invest up to €20m per operation, mainly in Europe.
Led by Pierre-Michel Passy, CEO, Edmond de Rothschild Investment Partners has invested in 46 life science companies to date.